Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum - PubMed (original) (raw)
. 1982 Nov-Dec;25(8):749-54.
doi: 10.1007/BF02553304.
- PMID: 7172942
- DOI: 10.1007/BF02553304
Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum
R Goslin et al. Dis Colon Rectum. 1982 Nov-Dec.
Abstract
The median survival of all patients with hepatic metastases from colorectal cancer referred to the Sidney Farber Cancer Institute during a five-year period was 12.5 months. Two major factors influenced survival. The first was extent of disease at presentation. The second was the histologic grade of the cancer. The median survival of patients presenting with the least disease, characterized by less than four liver nodules visible on liver scan (n = 38), normal liver size on physical examination (n = 60), normal liver function test results (n = 30), and normal performance status (n = 91), was between 18 and 24 months, regardless of treatment. The median survival of those few patients (n = 13) who had objective responses to a variety of treatments, most of whom also had minimal disease at presentation, was also 24 months. Patients whose tumors were poorly differentiated or who had abnormal performance status or weight loss of greater than 10 per cent at presentation survived only six months (median). Those with four or more liver nodules, hepatomegaly (greater than 16-cm vertical span on physical examination), or abnormal liver function test results, survived ten, eight, and 12 months (median), respectively. It is concluded that a significant group of patients survived longer than would have been predicted by earlier literature surveys after the diagnosis of colorectal cancer metastatic to the liver. It is suggested that future therapeutic trials, using survival as a measure of response of patients with liver metastases from colorectal cancer, must be prospectively controlled before selection factors can be differentiated from significant therapy effect.
Similar articles
- No treatment option for liver metastases from colorectal adenocarcinoma.
Palmer M, Petrelli NJ, Herrera L. Palmer M, et al. Dis Colon Rectum. 1989 Aug;32(8):698-701. doi: 10.1007/BF02555777. Dis Colon Rectum. 1989. PMID: 2752858 - Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis.
Finan PJ, Marshall RJ, Cooper EH, Giles GR. Finan PJ, et al. Br J Surg. 1985 May;72(5):373-7. doi: 10.1002/bjs.1800720514. Br J Surg. 1985. PMID: 3857947 - Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors.
De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG. De Jong KP, et al. Hepatology. 1998 Oct;28(4):971-9. doi: 10.1002/hep.510280411. Hepatology. 1998. PMID: 9755233 - A combined approach of neoadjuvant chemotherapy and surgery for colorectal liver metastases.
Esposito A, Mancini R, Ettorre G, Garufi C, Saracca E, Arcieri S, Cosimelli M. Esposito A, et al. J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):197-202. J Exp Clin Cancer Res. 2003. PMID: 16767931 Review. - Liver metastases from gastric carcinoma: A Case report and review of the literature.
Polkowska-Pruszyńska B, Rawicz-Pruszyński K, Ciseł B, Sitarz R, Polkowska G, Krupski W, Polkowski WP. Polkowska-Pruszyńska B, et al. Curr Probl Cancer. 2017 May-Jun;41(3):222-230. doi: 10.1016/j.currproblcancer.2017.03.003. Epub 2017 Mar 24. Curr Probl Cancer. 2017. PMID: 28625333 Review.
Cited by
- Resection of hepatic metastases from colorectal cancer. Biologic perspective.
Steele G Jr, Ravikumar TS. Steele G Jr, et al. Ann Surg. 1989 Aug;210(2):127-38. doi: 10.1097/00000658-198908000-00001. Ann Surg. 1989. PMID: 2667471 Free PMC article. Review. - Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study.
Makishima H, Yasuda S, Isozaki Y, Kasuya G, Okada N, Miyazaki M, Mohamad O, Matsufuji N, Yamada S, Tsuji H, Kamada T; Liver Cancer Working Group. Makishima H, et al. Cancer Sci. 2019 Jan;110(1):303-309. doi: 10.1111/cas.13872. Epub 2018 Dec 12. Cancer Sci. 2019. PMID: 30417485 Free PMC article. Clinical Trial. - Effect of interstitial laser hyperthermia in a murine model of colorectal liver metastases.
Muralidharan V, Malcontenti-Wilson C, Christophi C. Muralidharan V, et al. J Gastrointest Surg. 2001 Nov-Dec;5(6):646-57. doi: 10.1016/s1091-255x(01)80108-6. J Gastrointest Surg. 2001. PMID: 12086904 - Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).
Eggermont AM, Weimar W, Tank B, Dekkers-Bijma AM, Marquet RL, Lameris JS, Westbroek DL, Jeekel J. Eggermont AM, et al. Cancer Immunol Immunother. 1986;21(1):81-4. doi: 10.1007/BF00199382. Cancer Immunol Immunother. 1986. PMID: 3632919 Free PMC article. - Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases.
Pawlik TM, Choti MA. Pawlik TM, et al. Curr Oncol Rep. 2007 May;9(3):193-201. doi: 10.1007/s11912-007-0021-4. Curr Oncol Rep. 2007. PMID: 17430690 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical